JP Morgan raises price targets on Bel Fuse and DexCom shares
JP Morgan lifted its price target on Bel Fuse shares to $360 from $330 and on DexCom to $85 from $82, Dow Jones Newswires reports, citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan analysts raised their price target on Bel Fuse shares to $360 from $330. For DexCom, the target was increased to $85 from $82. The information was reported by Dow Jones Newswires, citing Benzinga's ratings data.
why it matters
Changes like these are routine: they reflect one bank's view on specific companies and usually have little effect on the broader market. For investors, company results and their own news matter more.
tags
instruments
sources
- Bel Fuse Price Target Raised to $360.00/Share From $330.00 by JP Morgan — Dow Jones Newswires, 30 October 2026 at 22:37 UTC
- DexCom Price Target Raised to $85.00/Share From $82.00 by JP Morgan — Dow Jones Newswires, 30 October 2026 at 22:43 UTC
- Exponent Price Target Raised to $100.00/Share From $90.00 by JP Morgan — Dow Jones Newswires, 30 October 2026 at 22:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗